BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, May 1, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 28, 2019
View Archived Issues
New ultrasensitive tau seed amplification assay for detection and subtyping of 4-repeat tauopathies
Read More
Replimune begins phase I study of RP-2 alone and with Opdivo in advanced solid tumors
Read More
Ozanimod demonstrates early histologic improvement in patients with active CD
Read More
Phase IIb data for upadacitinib as an induction therapy for patients with UC
Read More
SUVN-K-1806045 demonstrates analgesia in models of nociception and diabetic neuropathic pain
Read More
Preclinical results presented of a gene therapy for the treatment of retinitis pigmentosa
Read More
New antibiotic class fights colistin-resistant bugs
Read More
Metastases, tumors, similar in broad view, different in detail
Read More
Betta Pharmaceuticals divulges new PD-1/PD-L1 interaction inhibitors
Read More
Silverback Therapeutics discloses TGFR-1 inhibitors
Read More
Merck & Co. presents new hSTING agonists
Read More
FUJIFILM synthesizes beta-lactams
Read More
Y-mAbs announces presentation of data on naxitamab for neuroblastoma and osteosarcoma
Read More
TaiMed Biologics discontinues development of TMB-607
Read More
Antimalarial agents detailed in UCB patent
Read More
Arcutis plans phase III program with ARQ-151 for plaque psoriasis
Read More
Heat Biologics initiates first-in-human study of HS-130 with HS-110 in solid tumors
Read More
Molecular Targets meeting 2019: Bispecific matchmakers can improve antibodies, CARs
Read More
Zosano initiates enrollment in phase II/III study of C-213 for cluster headache
Read More
New phase II trial investigates JNJ-67864238 for moderate to severely active Crohn's disease
Read More
Novel class I HDAC inhibitor R8 demonstrates efficacy both in vitro and in vivo
Read More
CLN-081 begins first-in-human study for NSCLC with EGFR exon 20 insertion mutations
Read More
GlaxoSmithKline begins phase III development of gepotidacin
Read More
